Pioglitazone or metformin (DrugBank: Metformin, Pioglitazone)
21 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
6 | Parkinson disease | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
46 | Malignant rheumatoid arthritis | 0 |
49 | Systemic lupus erythematosus | 0 |
60 | Aplastic anemia | 0 |
67 | Polycystic kidney disease | 0 |
75 | Cushing disease | 0 |
77 | Growth hormone secreting pituitary adenoma | 0 |
81 | Congenital adrenal hyperplasia | 0 |
86 | Pulmonary arterial hypertension | 0 |
113 | Muscular dystrophy | 0 |
127 | Frontotemporal lobar degeneration | 0 |
158 | Tuberous sclerosis | 0 |
206 | Fragile X syndrome | 0 |
225 | Congenital nephrogenic diabetes insipidus | 0 |
233 | Wolfram syndrome | 0 |
265 | Lipodystrophy | 1 |
285 | Fanconi anemia | 0 |
299 | Cystic fibrosis | 0 |
301 | Macular dystrophy | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00362440 (ClinicalTrials.gov) | August 2006 | 9/8/2006 | Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome | A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial | HIV Lipodystrophy | Drug: Leptin;Drug: Pioglitazone or metformin;Drug: Placebo | Beth Israel Deaconess Medical Center | American Diabetes Association | Completed | 18 Years | N/A | All | 9 | Phase 2 | United States |